NexusPharma is a leading brand dedicated to providing innovative solutions in the field of cancer research and drug discovery. With a focus on addressing the unmet need for safer and more effective cancer drugs, NexusPharma collaborates with Fox Chase Cancer Center to develop patient-derived tumor disease models. These models, known as patient-derived xenograft (PDX) models, validate the effectiveness of cancer treatment compounds, serving as crucial tools in the discovery of novel therapeutics.

NexusPharma leverages genomic analysis, such as mRNA sequencing, to unravel critical cancer signaling networks and validate genetic profiles through quantitative methods. By building a database of compounds and their activities in PDX-derived cell lines, NexusPharma aims to establish a predictive correlation between biological targets and compound efficacy. As a member of Genesis Drug Discovery and Development (GD3), a preclinical Contract Research Organization, NexusPharma offers an integrated portfolio of drug discovery services, from target validation and assay development to lead optimization.

GD3's expertise spans biodesign, in vivo drug testing, and pharmacokinetics. Located in Hamilton, NJ, NexusPharma is at the forefront of advancing cancer research and is dedicated to improving patient outcomes. Contact us today for more information or to request a quote